Ascendis Pharma A/S ADR [ASND] stock is trading at $139.57, up 17.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ASND shares have gain 19.45% over the last week, with a monthly amount glided 0.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on September 05, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $180 for it. Previously, TD Cowen upgraded its rating to Buy on June 25, 2024, and elevated its price target to $175. On May 31, 2024, Stifel initiated with a Buy rating and assigned a price target of $200 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $150 on December 20, 2023. Oppenheimer downgraded its rating to Perform for this stock on April 05, 2023. In a note dated April 04, 2023, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $151 to $108.
Ascendis Pharma A/S ADR [ASND] stock has fluctuated between $85.29 and $161.00 over the past year. Currently, Wall Street analysts expect the stock to reach $177.29 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $139.57 at the most recent close of the market. An investor can expect a potential return of 27.03% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 343.17M for the trailing twelve months, which represents a drop of -24.87%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -1.11%, Pretax Profit Margin comes in at -1.5%, and Net Profit Margin reading is -1.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is 2.52 and Total Capital is 3.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 136.55 points at the first support level, and at 133.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 143.80, and for the 2nd resistance point, it is at 148.02.
Ratios To Look Out For
For context, Ascendis Pharma A/S ADR’s Current Ratio is 0.74. Also, the Quick Ratio is 0.44, while the Cash Ratio stands at 0.31. Considering the valuation of this stock, the price to sales ratio is 23.32.
